Tyler Zemla

3.1k total citations · 1 hit paper
83 papers, 1.7k citations indexed

About

Tyler Zemla is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Tyler Zemla has authored 83 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 25 papers in Cancer Research. Recurrent topics in Tyler Zemla's work include Colorectal Cancer Treatments and Studies (24 papers), Cancer Genomics and Diagnostics (17 papers) and Genetic factors in colorectal cancer (15 papers). Tyler Zemla is often cited by papers focused on Colorectal Cancer Treatments and Studies (24 papers), Cancer Genomics and Diagnostics (17 papers) and Genetic factors in colorectal cancer (15 papers). Tyler Zemla collaborates with scholars based in United States, Canada and Netherlands. Tyler Zemla's co-authors include Fang‐Shu Ou, Donna Niedzwiecki, Heinz‐Josef Lenz, Richard M. Goldberg, Federico Innocenti, Robert D. McBane, Charles D. Blanke, Alan P. Venook, Omar Kabbarah and Monica M. Bertagnolli and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Tyler Zemla

77 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

2019 375 citations Robert D. McBane, Waldemar E. Wysokiński et al. Journal of Thrombosis and Haemostasis profile →

Peers

Countries citing papers authored by Tyler Zemla

Since Specialization

Citations

This map shows the geographic impact of Tyler Zemla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tyler Zemla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tyler Zemla more than expected).

Fields of papers citing papers by Tyler Zemla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tyler Zemla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tyler Zemla. The network helps show where Tyler Zemla may publish in the future.

Co-authorship network of co-authors of Tyler Zemla

This figure shows the co-authorship network connecting the top 25 collaborators of Tyler Zemla. A scholar is included among the top collaborators of Tyler Zemla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tyler Zemla. Tyler Zemla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients 2024 ·Cancer Research Communications ·Yvonne Ayerki Nartey, Ju Dong Yang, Tyler Zemla, (unknown), Shadrack Osei Asibey, Mohamed El‐Kassas, (unknown), Amoako Duah, Adwoa Agyei‐Nkansah, Yaw Asante Awuku, Mary Afihene, (unknown), Jun Yin, Amelie Plymoth, Lewis R. Roberts	2
2	Atezolizumab plus bevacizumab (A+B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis of patient outcomes based on Child Pugh (CP) and ALBI liver function. 2024 ·Journal of Clinical Oncology ·(unknown), Tyler Zemla, (unknown), (unknown), Jennifer Gile, Nguyen H. Tran, Sakti Chakrabarti, Zhaohui Jin, Amit Mahipal	1
3	Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer 2024 ·JCO Precision Oncology ·(unknown), (unknown), Tyler Zemla, Nguyen H. Tran, Krishan R. Jethwa, Amit Mahipal, Jessica L. Mitchell, Cornelius A. Thiels, Kellie L. Mathis, Robert R. McWilliams, Joleen M. Hubbard, Frank A. Sinicrope, Qian Shi, Zhaohui Jin	6
4	Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Leila T. Tchelebi, (unknown), Koren Smith, Qian Shi, Thomas J. FitzGerald, Michael D. Chuong, Tyler Zemla, Eileen M. O’Reilly, Jeffrey A. Meyerhardt, Eugene J. Koay, Jessica Lowenstein, Ardaman Shergill, Matthew H. G. Katz, Joseph M. Herman	6
5	1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses 2024 ·Annals of Oncology ·Jennifer A. Chan, Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, (unknown), Jared D. Acoba, Ardaman Shergill, Edward M. Wolin, Þorvarður R. Hálfdánarson, Bhavana Konda, Nikolaos A. Trikalinos, Shagufta Shaheen, (unknown), (unknown), (unknown), Elise C. Kohn, (unknown), Eileen M. O’Reilly, Jeffrey A. Meyerhardt	0
6	SerpinB3/4 Expression Is Associated with Poor Prognosis in Patients with Cholangiocarcinoma 2024 ·Cancers ·Andréa Martini, (unknown), Tyler Zemla, Fowsiyo Ahmed, (unknown), Nasra H. Giama, Vincenza Guzzardo, Alessandra Biasiolo, Matteo Fassan, Jun Yin, Patrizia Pontisso, Lewis R. Roberts	2
7	Utility of methylated DNA markers for the diagnosis of malignant biliary strictures 2024 ·Hepatology ·(unknown), (unknown), Emily G. Barr Fritcher, Dragana Milosevic, Michael J. Levy, (unknown), John A. Martin, Bret T. Petersen, Barham K. Abu Dayyeh, Andrew C. Storm, Ryan Law, Eric J. Vargas, (unknown), Tyler Zemla, Sarah M. Jenkins, (unknown), Gregory J. Gores, Lewis R. Roberts, Benjamin R. Kipp, Vinay Chandrasekhara	2
8	Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501) 2024 ·Annals of Surgical Oncology ·Rebecca A. Snyder, Tyler Zemla, Qian Shi, (unknown), Syed A. Ahmad, Eileen M. O’Reilly, Joseph M. Herman, Matthew H. G. Katz	1
9	Association between physical activity and the time course of cancer recurrence in stage III colon cancer 2023 ·British Journal of Sports Medicine ·Justin C. Brown, (unknown), Qian Shi, Donna Niedzwiecki, Tyler Zemla, Félix Couture, Philip Kuebler, Pankaj Kumar, Judith O. Hopkins, Benjamin Kye Jyn Tan, Smitha Krishnamurthi, Eileen M. O’Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt	19
10	LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET) 2023 ·Annals of Oncology ·Jennifer A. Chan, Susan M. Geyer, (unknown), Michael V. Knopp, Spencer C. Behr, Tyler Zemla, Jared D. Acoba, Ardaman Shergill, Edward M. Wolin, Þorvarður R. Hálfdánarson, Nikolaos A. Trikalinos, Bhavana Konda, (unknown), (unknown), (unknown), Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly, Jeffrey A. Meyerhardt	18
11	Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance) 2023 ·Cancer ·Justin C. Brown, (unknown), Qian Shi, Tyler Zemla, Félix Couture, Philip Kuebler, Pankaj Kumar, Benjamin Tan, Smitha Krishnamurthi, Victor T. Chang, Richard M. Goldberg, Alan P. Venook, Charles D. Blanke, Eileen M. O’Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt	2
12	LB 02.1 Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial 2023 ·Research and Practice in Thrombosis and Haemostasis ·Robert D. McBane, Charles L. Loprinzi, Shaker R. Dakhil, Adedayo A. Onitilo, Krishna Gundabolu, Michael J. Drescher, (unknown), (unknown), David García, (unknown), (unknown), Alfonso Tafur, Stanislav Henkin, Charles Kuzma, (unknown), (unknown), Tyler Zemla, Shannon McCue, Damon E. Houghton, Waldemar E. Wysokiński	2
13	Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance) 2022 ·Journal of Clinical Oncology ·Justin C. Brown, (unknown), Qian Shi, Charles S. Fuchs, (unknown), Donna Niedzwiecki, Tyler Zemla, Félix Couture, Philip Kuebler, Pankaj Kumar, DeQuincy Andrew Lewis, Benjamin Kye Jyn Tan, Smitha Krishnamurthi, Eileen M. O’Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt	24
14	Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma 2022 ·Targeted Oncology ·Jennifer Gile, (unknown), Tyler Zemla, Qian Shi, Zhaohui Jin, Steven R. Alberts, Robert R. McWilliams, Wen Wee, Mitesh J. Borad, Tanios Bekaii‐Saab, Nguyen H. Tran, Amit Mahipal	4
15	Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer 2022 ·Clinical Lung Cancer ·Steven E. Schild, (unknown), Christine M. Bestvina, Terence M. Williams, (unknown), Anurag Kumar Singh, Thomas E. Stinchcombe, Joseph K. Salama, (unknown), Tyler Zemla, Narjust Duma, Stephen G. Chun, Arya Amini, David Kozono, Colleen Watt	12
16	Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer 2021 ·Future Oncology ·Ciara C. O’Sullivan, Karla V. Ballman, Linda McCall, Anuhya Kommalapati, Tyler Zemla, Anna Weiss, Melissa P. Mitchell, Victoria Blinder, Nadine Tung, William Irvin, Myoung-Hee Lee, Matthew P. Goetz, W. Fraser Symmans, Virginia F. Borges, Ian E. Krop, Lisa A. Carey, Ann H. Partridge	19
17	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial 2021 ·The Oncologist ·Aminah Jatoi, Fang‐Shu Ou, Daniel H. Ahn, Tyler Zemla, Jennifer Le‐Rademacher, Patrick M. Boland, Kristen K. Ciombor, Nisha L. Jacobs, Boris Pasche, James M. Cleary, Jeannine S. McCune, Katrina S. Pedersen, Afsaneh Barzi, E. Gabriela Chiorean, Erica N. Heying, Heinz‐Josef Lenz, Jeff A. Sloan, Axel Grothey, Mario E. Lacouture, Tanios Bekaii‐Saab	5
18	Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial breakdown → 2019 ·Journal of Thrombosis and Haemostasis ·Robert D. McBane, Waldemar E. Wysokiński, Jennifer Le‐Rademacher, Tyler Zemla, Aneel A. Ashrani, Alfonso Tafur, Usha Perepu, Daniel M. Anderson, Krishna Gundabolu, Charles Kuzma, Juliana Perez Botero, Roberto A. Leon Ferre, Stanislav Henkin, Charles J. Lenz, Damon E. Houghton, Prakash Vishnu, Charles L. Loprinzi	375
19	Acquisition of sexual orientation and gender identity data among NCI Community Oncology Research Program practice groups 2018 ·Cancer ·Elizabeth Cathcart-Rake, Tyler Zemla, Aminah Jatoi, Kathryn E. Weaver, Heather B. Neuman, Anne E. Kazak, Ruth C. Carlos, (unknown), Joseph M. Unger, Nicholas M. Pajewski, Charles Kamen	38
20	A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER). 2017 ·Journal of Clinical Oncology ·John H. Strickler, Donna Niedzwiecki, Tyler Zemla, Andrea Cercek, Marwan Fakih, Kimmie Ng, Federico Augusto Sanchez, Christina Wu, Scott Peterson, (unknown), Axel Grothey, Tanios Bekaii‐Saab	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact